Surgical Navigation Systems Market: Growth Opportunities, Segmentation, Competitive Landscape and Regional Analysis
Global Surgical Navigation Systems Market is expected to register a CAGR of6.27% during the forecast period, with a market value of USD 1,324.63 Million till 2025. Surgical navigation systems are an integral part of computer-assisted surgery (CAS). Computer-assisted surgery makes minimally invasive surgical solutions feasible. The surgeon gets rapid information to determine where the patient needs to make incisions and perform surgery.
The global surgical navigation systems market has been segmented by technology, application, and end-user. The market, based on technology, has been bifurcated into electromagnetic based navigation systems, optical navigation systems, and others.
Based on the application, the surgical navigation systems market has been segregated into neurosurgery, orthopedic surgery, ENT surgery, dental surgery, and others. The global surgical navigation systems market, based on the end-user, has been segmented hospitals, ambulatory surgical centers, and others.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/7863
The Global Surgical Navigation Systems Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to dominate the global surgical navigation systems market. This can be attributed to the growing surgical procedure and the increasing incidence of orthopedic surgeries in the region. In 2014, according to the American Academy of Orthopedic Surgeons (AAOS), about 370,770 total hip replacements (THR) and around 680,150 total knee replacements (TKR) surgeries were performed in the US. By 2030, primary THR is estimated to grow by 171% and primary TKR is projected to grow by up to 189%, for an estimated about 635,000 and 1.28 million procedures, respectively.
The European market for surgical navigation systems is expected to be the second-largest during the review period. The rising number of neurosurgeries, coupled with various government initiatives, is expected to boost the growth of the regional market. For instance, The Getting It Right First Time (GIRFT), a National Health Service (NHS) improvement program delivered in partnership with the Royal National Orthopedic Hospital NHS Trust, projected that about 75,000 patients get admitted for neurosurgery each year in NHS hospitals across England. Additionally, the growing number of neurosurgeries in Europe is also fueling the market growth.
Asia-Pacific is expected to be the fastest-growing market owing to the geriatric population and the rising number of orthopedic surgeries in the region. Also, there is growing awareness about the technological advancements, and the accessibility of several devices for surgical navigation is likely to drive the market growth during the forecast period.
The market in the Middle East & Africa is expected to witness steady growth due to limited access and healthcare affordability among the population in the Middle Eastern countries. Growing awareness regarding the health and availability of new treatment and diagnostic procedures is expected to fuel the market growth in this region.
Access Report Details @ https://www.marketresearchfuture.com/reports/surgical-navigation-systems-market-7863
MRFR recognizes the following companies as the Key Players in the Global Surgical Navigation Systems Market— Medtronic PLC (Ireland), Brainlab (Germany), and Stryker Corporation (US).
Key Findings of the StudyThe Global Surgical Navigation Systems Market is estimated to reach USD 1,324.63 million by 2025 at a CAGR of 6.27% during the assessment periodThe Americas accounted for the largest share of the global surgical navigation systems market due to the rising geriatric population and product launches.Based on technology, the electromagnetic based navigation systems segment accounted for the largest market share of 48.39% in 2018Based on application, the neurosurgery segment accounted for the largest market share of 32.14% in 2018On the basis of end user, the hospital segment accounted for the largest market share of 45.99% in 2018
Artificial Kidney Market: Historical, Current and Projected Market Size, Competitive landscape & Forecast 2027
According to MRFR analysis, the Artificial Kidney Market is expected to register a CAGR of 95.54% during the forecast period of 2019 to 2025 and expected to reach USD 2,795.01 Million by 2025. The global artificial kidney market is expected to grow at a rapid pace. The increasing research and development for enhancement of the dialysis process, rise in cases of chronic kidney diseases, and low availability of kidney donors are some of the factors influencing the growth of the market. However, issues with the size of artificial kidney and engineering problems associated with the devices are expected to hamper the growth of the market. The rise in awareness about renal failure diseases and changing lifestyle is expected to drive the market growth. One in three Americans is at risk for developing kidney disease due to rapidly rising rates of diabetes and high blood pressure. Moreover, the National Institutes of Health (NIH), declared March as National Kidney Month to raise awareness about chronic kidney diseases. The rise in awareness about chronic kidney diseases through campaign launches to opt for ambulatory dialysis will further increase the demand for the artificial kidney.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/8747
On a regional basis, the market has been segmented into four major regions, including the Americas, Europe, Asia-Pacific, and Middle East & Africa.
Americas are anticipated to dominate the global artificial kidney market owing to the presence of major players, rising research & development by private & public organizations, and rise in the number of cases of chronic kidney diseases. Europe is expected to account for the second-largest market in the global artificial kidney market owing to the rise in technological advancement in the field of medicine & technology and the growing geriatric population. Furthermore, Asia-Pacific expected to be the fastest-growing segment owing to a rise in the prevalence of renal failure cases, a rise in disposable income, increasing investment by government bodies, and rising opportunities for major players to invest in the region. The Middle East & Africa accounted for the least market share. However, untapped markets and a rise in awareness among patients about the advantages of artificial kidney would provide growth opportunities in the coming years.
The Global Artificial Kidney Market has been segmented into Type and Dialysis.
By type, the market has been segmented into the wearable artificial kidney and implantable artificial kidney. The wearable artificial kidney is expected to hold the largest market share owing to the increasing number of patients suffering from renal failure and the technical advantages of artificial organs.
On the basis of dialysis, the global artificial kidney market is bifurcated into hemodialysis, peritoneal dialysis, and combination. The hemodialysis segment accounted for the largest market share owing to the rise in the number of hemodialysis procedures.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/artificial-kidney-market-8747
Key Players Some of the key players in the global artificial kidney market are Kawasumi Laboratories, Inc. (Japan), Blood Purification Technologies Inc., AWAK Technologies Pte.Ltd.(Singapore), Triomed AB. (Sweden), Asahi Kasei Medical Vo., Ltd, and others.
Wearable Ambulatory Monitoring Devices Market Global Size, Future Scope, Demands and Projected Industry Growths to 2027
Global Wearable Ambulatory Monitoring Devices Market is expected to register a CAGR of 6.48% during the forecast period with a market value of USD 4,990.8 Million till 2025. Wearable ambulatory monitoring devices are portable electrocardiograph machines attached either to patients’ body or inserted below the skin. They are used to record heart rhythms. Each type of monitor has differentiated in terms of length of heart rhythm recording time.
The Global Wearable Ambulatory Monitoring Devices Market has been segmented by product type. Based on product type, wearable ambulatory monitoring devices market has been segregated into cardiac event monitors, Holter monitor, mobile cardiac telemetry devices, and others.
Request For Free Sample Copy : https://www.marketresearchfuture.com/sample_request/8740
The Global Wearable Ambulatory Monitoring Devices Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas are likely to dominate the global wearable ambulatory monitoring devices market. This can be attributed to the high prevalence of cardiovascular diseases in the region. According to the American Heart Association (AHA), in 2015, an estimated 4 million Americans suffered from recurrent arrhythmias. Moreover, the rising health expenditure per person and increasing demand for advanced treatment options are also expected to drive market growth.
The European market for wearable ambulatory monitoring devices is estimated to be the second-largest during the review period. The high number of cases of arrhythmias in Europe is expected to boost the growth of the regional market. For instance, according to the statistics published by the National Health Service in 2018, arrhythmias are experienced by more than 2 million people per year in the UK. Additionally, the prevalence of high blood pressure is also increasing in Europe, which is further fueling the market growth.
Asia-Pacific is estimated to be the fastest-growing market owing to the increase in product launches in the region. For instance, in December 2017, Abbott Laboratories announced the launch of its first smartphone-compatible insertable cardiac monitor to detect arrhythmias in India. Moreover, the high prevalence of chronic diseases is also positively affecting the market growth.
The market in the Middle East & Africa is expected to witness steady growth due to the rising awareness regarding health and availability of new treatment & diagnostic methods in the Middle Eastern countries.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/wearable-ambulatory-monitoring-devices-market-8740
MRFR recognizes the following companies as the Key Players in the Global Wearable Ambulatory Monitoring Devices Market— General Electric Company (US), ACS Diagnostics (US), BioTelemetry (US), iRhythm Technologies, Inc. (US), Medicomp Inc. (US), Medtronic PLC (Europe), Preventice Solutions, Inc. (US), Telerhythmics, LLC (US), Hill-Rom Services Inc. (US), and ZOLL Medical Corporation (US).
Meningococcal Vaccines Market Size Industry Insights, Top Trends, Drivers, Growth and Forecast to 2027
According to MRFR analysis, Meningococcal Vaccines Market has a demand for USD 172 Million doses in 2019. Further, the global estimated supply in 2019 is expected to be 203 Million doses.
Despite broad and effective commitment from the global health community in meningitis A (MENA) vaccination in the meningitis belt, low manufacturing capacity and high prices across other meningococcal vaccine types have hindered access to these vaccines over the past several years. A more in-depth knowledge will benefit addressing these long-standing access issues and the development of the WHO global roadmap for overcoming meningitis by 2030. This is expected to set goals for disease control and vaccination for meningococcal meningitis on a global level.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/8622
Need for meningococcal vaccines is characterized by significant use outside of routine immunization: subnational use, immunization of special risk groups such as military personnel or travelers, private market use, or recommended but not-reimbursed immunization. In 2019, in addition to the 39 mostly HIC and meningitis belt countries that use meningococcal vaccines in national immunization programs NIPs, 27 countries use meningococcal vaccines only for special risk groups. National routine uses in 2019 accounts for approximately 100 million doses across all countries except for China.
However, other countries in the African and Eastern Mediterranean region have indicated interest in introducing a multivalent, conjugate vaccine into routine National Immunization Program Schedule, but have strived to access these vaccines due to the high price and limited availability.
Further, in 2018, 3.2 million doses were available in the Global stock, compared with 5 million doses that professionals forecast will be needed each year in the future, with more C- and W-containing vaccines needed to focus on the rising incidence of those serogroup globally.
Overall, demand for MenACWY conjugate is expected to increase over the short- and mid-term, as HICs and MICs show a growing inclination for immunization strategies targeting multiple serogroups and as Hajj pilgrims increasingly use MenACWY conjugate due to withdrawal of polysaccharide products.
The Global Meningococcal Vaccines Market has been segmented based on treatment type and end-user. The market, based on treatment type, has been divided into the meningococcal conjugate vaccine, polysaccharide, and subcapsular vaccine. In terms of end-user, the global meningococcal vaccines market has been segmented into hospitals & clinics, research & academic institutes, and others.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/meningococcal-vaccines-market-8622
Some of the key players in the Global Meningococcal Vaccines Market are Baxter International, Pfizer Inc., Novartis Pharmaceuticals Canada Inc, Sanofi S.A., JN-International Medical Corporation, Biomed Pvt. Ltd., Serum Institute of India Ltd., and GlaxoSmithKline among others.
According to MRFR analysis, Cell Counting Market is expected to register a CAGR of 5.8% during the forecast period of 2019 to 2025 and was valued at USD 8.47 Billion in 2018.
Cell counting is important for research and serves as one of the major steps in the majority of experiments. It is effectively utilized for maintaining cell cultures. Moreover, another important application of cell counting can be seen in the diagnosis of chronic diseases like cancer. For instance, an increase in the number of white blood cells (WBC) may indicate the possibility of cancerous growth in the body. Thus, cell counting is important for microbiology, hematology and other medical specialties.
The growth of the global cell counting market is determined by numerous factors such as increasing R&D expenditure, rising prevalence of cancer, and product launches. However, the high cost of devices and product recalls are projected to restrain the growth of the market during the forecast period.
The Global Cell Counting Market is currently dominated by several market players. The key players are involved in product launches, expansion, and strategic collaborations to strengthen their market positions. Recently in April 2019, the Nexcelom Bioscience LLC launched Cellaca MX automated cell counter.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/8600
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is anticipated to hold the largest market share owing to the increase in the incidence of cancer and the presence of well-established pharmaceutical and biotechnology industry. The cell counting market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
The European cell counting market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cell counting market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the presence of a large patient pool and expansion of healthcare facilities, the market in Asia-Pacific is expected to be the fastest-growing. The cell counting market in the Middle East & Africa has been divided into the Middle East and Africa.
The Global Cell Counting Market has been segmented based on product, application, and end-user.
The market, based on type, has been divided into consumables and instruments. The consumable segment is likely to hold maximum market share in the global cell counting market. This due to the repeated purchase of the consumable compared with instrument products.
The global cell counting market based on application has been segregated into research application, clinical & diagnostic application, and others. The research application segment is anticipated to hold the largest share in the market due to the rising funding for stem cell research.
The end-user segments of the market are pharmaceutical and biotechnology companies, hospitals, research institutes, and others. The pharmaceutical and biotechnology companies’ segment is expected to hold the largest share of the market, as these are used cell counting products in research and development of new drugs and therapies.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/cell-counting-market-8600
Some of the Key Players in the Global Cell Counting Market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Logos Biosystems, Inc. (South Korea), Olympus Corporation (Japan), Agilent Technologies, Inc. (US), PerkinElmer, Inc. (US), Sysmex Corporation (Japan), Abbott Laboratories (US), and others.
Medical Drones’ Market: Business Opportunities, Competition & Key Companies, Current Trends and Challenges
According to MRFR analysis, Medical Drones’ Market is expected to register a CAGR of 24.4% during the forecast period of 2019 to 2025 and was valued at USD 85.84 Million in 2018.
Medical drones help to carry medical supplies that consist of medications, vaccines, and medical aids, among others. These drones are used in isolated or inaccessible areas for the rapid and secure distribution of medical supplies and also to war-torn areas from medical facilities.
The growth of the global medical drones market is attributed to factors such as the rising number of government initiatives, applications of medical drones, research & development activities, and public acceptance. However, strict laws associated with the approval of medical drones are likely to hamper the growth of the market during the forecast period.
The key players in the medical drones market are aggressively involved in R&D, geographic expansions, product launches, and strategic collaborations to strengthen their market positions.
Request For Free Sample Copy : https://www.marketresearchfuture.com/sample_request/8596
The market has been divided by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is anticipated to hold the largest market share throughout the forecast period owing to the aggressive R&D activity by public and private organizations in the US, raising awareness, and strategic alliances between key players. For instance, between July to Sep 2019, Zipline a US-based drone company entered the partnerships with the DoD and Naval Medical Research Center to provide drones throughout four multinational military forces exercises in Australia. The medical drones market in the Americas has further been divided into North America and Latin America, with the North American market further divided into the US and Canada.
The European medical drones market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The medical drones market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the presence of a large patient pool and expansion of healthcare facilities, the market in Asia-Pacific is expected to be the fastest-growing during the forecast period. The Medical Drones market in the Middle East & Africa has been divided into the Middle East and Africa.
The Global Medical Drones Market has been segmented based on applications and end-user.
The market, based on application, has been segmented into blood transfer, pharmaceutical/drug transfer, vaccine transfer, and others. The blood transfer segment is expected to witness healthy growth during the forecast period owing to the rising number of deaths due to severe bleeding. For instance, each year around 2 million people die from blood loss or hemorrhaging across the globe.
The global medical drones market based on end-user has been segregated into emergency medical services, blood banks, and others.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/medical-drones-market-8596
Some of the Key Players in the Global Medical Drones Market are DJI (China), DHL (Germany), Embention (Spain), Flirtey (US), Matternet (US), Vayu (US), Zipline (US), EHang (China), TUDelft (The Netherlands), and others.
According to MRFR analysis, Thalassemia Treatment Market is expected to register a CAGR of 10.4% during the forecast period of 2019 to 2025 and was valued at USD 1890.4 Million in 2018.
Thalassemia is an inherited blood disorder that is characterized by inadequate hemoglobin and fewer red blood cells in the body than normal. Hemoglobin is the substance in red blood cells that allows them to carry oxygen. The inadequate hemoglobin and fewer red blood cells of thalassemia may cause anemia.
The growth of the Global Thalassemia Treatment Market is driven by various factors such as rising incidence of thalassemia, increasing pipeline drugs in thalassemia, rise in awareness regarding available treatment options for the treatment of thalassemia, growing public awareness related to preventive care and rise in demand for improved curative gene therapy. However, stringent regulatory policies and high treatment costs are expected to curb the growth of the global thalassemia treatment market.
The global thalassemia treatment market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/8595
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of thalassemia and rising per capita healthcare expenditure. The thalassemia treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European thalassemia treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The thalassemia treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Increasing government initiatives to promote the thalassemia treatment technique is expected to boost the growth of the thalassemia treatment market in Asia-Pacific and is expected to be the fastest-growing. The thalassemia treatment market in the Middle East & Africa has been divided into the Middle East and Africa.
Thalassemia Treatment Market Segmentation
The Global Thalassemia Treatment Market has been segmented based on type, treatment, and end-user.
The market, based on type, has been divided into alpha-thalassemia and beta-thalassemia. The alpha-thalassemia segment is likely to be the fastest during the forecast period as there is an increased incidence of alpha-globin disorders in the US and other Western nations.
The global thalassemia treatment market has been segmented based on treatment, into blood transfusions, iron chelation therapy, folic acid supplements, gene therapy, and bone marrow transplants. The blood transfusions segment is expected to be the fastest market as low risks are involved due to careful blood screening. For instance, about 56,000 population have major thalassemia, and there are at least 30,000 people that need regular blood transfusions to survive and 5,500 die perinatally due to alpha-thalassemia major. As a result, increasing the need for blood transfusions would boost the growth of the thalassemia treatment market.
The end-user segment of the market includes hospitals and clinics, diagnostic laboratories, and others. The hospitals and clinics segment is expected to hold the largest share of the market due to the increase in the number of hospital admissions for the treatment of thalassemia across the globe.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/thalassemia-treatment-market-8595
Some of the Key Players in the Global Thalassemia Treatment Market are Novartis AG (Switzerland), Kiadis Pharma (Netherlands), Sangamo Therapeutics (US), Gamida Cell (Israel), Acceleron Pharma, Inc. (US), CELGENE CORPORATION (US), and Bluebird Bio, Inc. (US).
The global Cough Syrup Market is expected to register a CAGR of 3.45% to reach USD 5,139.63 million by 2026. Rise of respiratory disorders, common cold, and the surge in pollution levels can drive the market growth exponentially. According to the Forum of International Respiratory Societies (FIRS), indoor air pollution, pollution from traffic, and tobacco smoke are main causes of air pollution. This is evident with 4.3 million deaths have been caused by air pollution, as per the report by WHO. The large elderly populace and the active pharmaceutical sector are other drivers of the market.
The misuse of cough syrup by consumers can deter its market growth.
The global cough syrup market has been segmented into product type, category, and application.
Based on product type, the market has been segregated into combination and individuals. Combination product type has been further classified as dextromethorphan + guaifenesin, guaifenesin + pseudoephedrine, and brompheniramine + pseudoephedrine. The individual product type has been further divided into dextromethorphan, guaifenesin, ambroxol, and codeine.
Based on the category, the market has been segmented into cough suppressants and expectorants.
By application, the cough syrup market has been categorized as adults and child.
Request For Free Sample Copy : https://www.marketresearchfuture.com/sample_request/8217
The global cough syrup market, based on region, has been divided into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas is expected to hold a maximum share of the global cough syrup market and is projected to register a CAGR of 3.16% during the forecast period. Presence of significant market players, strategic acquisitions by major players, increasing cases of respiratory disorders, and availability of advanced medications for the treatment of chronic obstructive pulmonary disease (COPD) are main drivers of the regional market. The low growth risk and high competition can ensure the steady growth of the market.
Europe accounts for the second-largest, in the global cough syrup market, majorly due to the presence of key players such as GlaxoSmithKline, Reckitt Benckiser Group PLC, and Novartis. Moreover, the purchase of over-the-counter (OTC) syrups from retail pharmacies over the preference of the local healthcare provider can bode well for the market.
APAC is estimated to be the fastest-growing market due to the continuous development in developing countries such as India and China. High prevalence of respiratory disorders due to vehicular pollution, tobacco smoke, exposure to air pollutants at home and the workplace, and indoor air pollution from biological agents are major drivers of the regional cough syrup market. The prevalence of smog due to industrial pollution in China can drive the product sales.
The MEA cough syrup market is driven by advances in healthcare infrastructure, increasing healthcare expenditure, and increasing per capita disposable incomes of the people in the UAE and Saudi Arabia. Africa is the least developed region with limited healthcare resources and facilities for the people. The low growth rate due to less developed and less efficient health systems is hampering the growth of the market.
Browse Complete Toc :https://www.marketresearchfuture.com/reports/cough-syrup-market-8217
Reckitt Benckiser Group PLC, Merck KGaA, Johnson & Johnson Services, Inc., Novartis AG, Sanofi, Procter & Gamble, Abbott, Acella Pharmaceuticals, LLC, Pfizer, Inc., and GlaxoSmithKline PLC are key players of the global cough syrup market.
Insulin Delivery Devices Market Size Industry Insights, Top Trends, Drivers, Growth and Forecast to 2027
Overview:The Insulin Delivery Devices Market is growing at a rapid pace; mainly due to the rapidly increasing number of diabetic populations. Insulin delivery devices are adaptable & lifestyle friendly, and hence these are garnering huge popularity and advancement due to its programmable physiologic technique for the delivery of insulin.
The current research and development activities that are coordinating the two technologies, “sensor-augmented” and “sensor-driven” to develop pumps with completely automated & independent sensing and delivery system are expected to escalate the market on the ascending global heights.
Acknowledging the burnished growth, the market perceives currently, Market Research Future (MRFR) in its recently published study report asserts that the global insulin delivery devices market is expected to accrue exponentially by 2020, registering 7.9 % CAGR between 2014 and 2020.
Additional factors fostering the growth of this market include the rise in the obese population, the prevalence of diabetes that is rising significantly, and the spreading awareness towards diabetic care, worldwide. The wide uptake of technological advancements in drug delivery devices is acting as a major tailwind that is pushing up the market growth.
The number of the population diagnosed with diabetes is projected to increase at a tremendous rate. Thus, if these trends linearly continue over the next couple of years, it will dramatically increase the number of populations diagnosed with diabetes which, in turn, will substantially foster the demand for insulin delivery devices.
With the rising number of diabetic patients, the demand for insulin delivery devices is expected to surge, thus resulting in exploding the size of the global insulin pumps market.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/851
Global Insulin Delivery Devices Market – Segments
The MRFR analysis is segmented into two key dynamics for the convenience of understanding;
By Type : Insulin Syringe, Insulin Pumps, Insulin Pens, Insulin Jet Injectors and others (jet injectors, transdermal patches, and inhalers).
By Regions: Europe, North America, Asia Pacific, and the Rest-of-the-World (RoW).
Insulin Delivery Devices Market – Geographical Analysis:
The well-developed regions of North America and Europe account for the leading markets for insulin delivery devices, globally. The developed economy allows these regions to have an edge over other regions, in every aspect, be it technology or healthcare. Also, factors such as the growing diabetic population, increasing technological advancements in the healthcare industry, and the faster uptake of technology are driving the insulin delivery devices market in these regions.
The U.S backed by a higher GDP, higher per capita healthcare expenses, and technological advancements, is expected to lead the insulin delivery devices market in North America. Whereas, Germany will lead the European market, heading with the presence of its large medical device industry.
Insulin delivery devices market in the Asia Pacific region is growing rapidly owing to the huge patient population of Type -1 diabetes and the rising economy in countries such as China, Vietnam, Indonesia, and India.
India, due to the presence of a greater number of type-2 diabetes patients is expected to dominate the regional market for insulin delivery devices. Simultaneously, the demand for quality devices in healthcare rising alongside the rapidly developing healthcare technology is expected to lead the market growth in the APAC region.
Report Details @ https://www.marketresearchfuture.com/reports/insulin-delivery-devices-market-851
Global Insulin Delivery Devices Market – Competitive Landscape
The rapidly growing market of insulin delivery devices appears fiercely competitive and fragmented with many large and small-scale players alongside new entrants forming a competitive landscape. The fierce competition in the anti-diabetic drug market has forced many players to developed delivery devices as an effective way to control the fall in revenues.
Matured players are increasingly seeking market expansion through various strategic initiatives such as mergers and acquisitions, increasing investments, innovation, and R&D to develop cost-effective product portfolio. They are also expanding their sales operations in emerging markets such as India and China to gain high market shares. The partnership formed are helping the companies to reduce the development costs associated with the insulin delivery devices.
These players possess state-of-the-art developing labs and strong sales and distribution network that can help them to gain the leadership position in the market. An ever-increasing emphasis on inbound lead generation over branding-oriented efforts has been observed among the marketers.
The fervent players leading the global insulin delivery devices market include Sanofi, Novo Nordisk, Eli Lilly, Medtronic, Copernicus, Beta Bionics, InsuJet, MannKind, SHL Group, Roche, and Becton Dickinson (BD) among others.
Industry/ Innovation/ Related News:
December 14, 2018 –– Eli Lilly and Company (US), a leading global pharmaceutical company announced its expanded collaboration with Evidation Health, Inc. (US), a technology company involved in the development of digital tools and technologies especially for the healthcare industry. The collaboration with a multi-year agreement will provide Lilly with global access to Evidation’s Andromeda data platform to analyze the data through Smartphones & Connected Sensors.
Studying Evidation’s data platform will help Lilly to analyze data from continuous glucose monitors, insulin pumps, and real-world information to build a connected ecosystem that includes an automated insulin delivery device and connected insulin pen.
Electrochemical Biosensors Market Research Report – Forecast to 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.
Increasing diabetic population, rising prevalence of chronic and lifestyle diseases, and increasing demand for point-of-care-testing (POCT) devices are major factors contributing to the growth of the market. Additionally, increasing application of biosensors in various industries also accelerates the growth of the market. However, the market growth is restrained by various factors such as strict regulatory requirements, reimbursement policies issues in healthcare systems.
In addition, POCT testing offers various advantages such as cost reduction for laboratory testing, faster results, and increased patient satisfaction. Hence, increasing demand of point of care testing would drive the growth of biosensors market.
The global electrochemical biosensors market is growing at the CAGR of 9.7%.
Browse Full Report @ https://www.marketresearchfuture.com/reports/electrochemical-biosensors-market-2792
Key players in the electrochemical biosensors:
Key players in the automated devices market are F. Hoffmann-La Roche AG (Germany), Medtronic Plc. (U.S.), Bayer AG (Germany), Abbott (U.S.), I-SENS, Inc. (South Korea), Siemens (U.S.) and others. The main focus of these players is tapping the market in developing regions across the globe. Also product differentiation plays an important role for sustaining the growth of key players in the market.
F. Hoffmann-La Roche AG:
Headquartered in Basel, Switzerland; F. Hoffmann-La Roche AG is a company manufacturing and marketing number of innovative diagnostic tests and medicines, across the globe. The company offers various products in the pharmaceutical, diagnostics and research industry.
June, 2017: F. Hoffmann-La Roche AG acquired mySugr to form a leading platform for digital diabetes management
August, 2015: F. Hoffmann-La Roche AG acquired GeneWEAVE to strengthen offerings in microbiology diagnostics. Roche will pay GeneWEAVE shareholders $190 million upfront and up to USD 235 million in contingent product related milestones
February 2015 : F. Hoffmann-La Roche AG announced the collaboration with BioMed X for the development of Nanomaterial-Based Biosensors for Near-Patient Testing
September 2014: F. Hoffmann-La Roche AG launched Elecsys anti-Müllerian Hormone (AMH) fertility test for assessment of ovarian reserve for pregnancy
Request For Free Sample Copy : https://www.marketresearchfuture.com/sample_request/2792
Founded in 1949, Medtronic plc is a global healthcare solutions company committed to improving the lives of people through their medical technologies, services, and solutions.
October, 2016: Medtronic plc received an approval for its suite of cardiac rhythm and heart failure devices and leads to be scanned in both 3 and 1.5 Tesla (T) magnetic resonance imaging (MRI) machines. This FDA approval will help the company to strengthen its position in MRI machines segment.
December, 2015: Medtronic plc and Samsung came together in an alliance to accelerate the development of digital health solutions for the millions of people suffering from chronic pain, movement disorders, incontinence, and other conditions who could benefit from neuromodulation therapy. Due to this Medtronics seeks to deliver real-time data to the patients and the physicians so they effectively find the cure for the tracked symptoms.
Headquartered in Illinois, USA, Abbott focuses on discovery, development, manufacture, and sale of health care products. The company operates through four segments namely, established pharmaceutical products, diagnostic products, nutritional products, and vascular products. Additionally, the company has two non-reportable segments, namely, diabetes care and medical optics. The diabetes care division of the company is located in California, U.S. and provides blood glucose meters, blood glucose test strips, sensors, data management decision software, and accessories.
June, 2017: Alere shareholders approve amended merger with Abbott. This merger will further strengthen the global presence of the company.
October, 2016 : Abbott announced collaborations with Celgene and Agios for diagnostic identification of IDH mutations. The agreement focuses on the development and commercialize the diagnostic tests.
April, 2016: Abbott received FDA approval for its companion diagnostics “Vysis CLL FISH probe kit” in Leukemia. The kit is used to detect the 17p deletion in chronic lymphocytic leukemia patients, the target population of a new drug from AbbVie.
Siemens is a leading global healthcare company continuously developing their portfolio from medical imaging and laboratory diagnostics to adding managed services, consulting, and healthcare IT services apart from further technologies for therapeutic and molecular diagnostics.
September, 2016: Siemens launched the combination of the Modularis urological shock wave unit and the flat detector technology of the mobile C-arm Cios Fusion. Since, constantly switching between two or even three different control units would be complicated and could lead to errors, the Modularis’ central control unit is a better option. This will help Siemens to strengthen its position in the market.